DeviceTalks Boston Archives - Page 5 of 5

How Insulet created its next-gen Omnipod 5

Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January.

Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Users can use a dedicated handheld controller or control the system with a secure app on their smartphone, marking another first.

Join us at DeviceTalks Boston on May 10-11, 2022, for a keynote interview with Insulet CEO Shacey Petrovic to learn about the story behind the game-changing Omnipod 5.

DeviceTalks Boston will unite medtech’s most innovative professionals and help attendees clear troublesome bottlenecks in the critical stages of medical device development. We will explore the trends and technology that are shaping the future of the medical device…

Where are LVADs headed in the future?

The HeartMate 3 LVAD. [Image courtesy of LVAD]

Abbott (NYSE:ABT) became the dominant provider of left ventricular assist devices (LVADs) after Medtronic’s decision to leave the market last year.

The Abbott HeartMate 3‘s advantages include its Full MagLev flow technology — which involves a free-floating magnetically levitated rotor that prevents surface-to-surface contact that could cause blood trauma. In addition, system batteries provide up to 17 hours of uninterrupted power, and the LVAD’s creators designed the system’s HeartMate Touch communications system to be intuitive and user-friendly.

Join us at DeviceTalks Boston on May 10-11, 2022, and find out where top Abbott officials would like to take LVADs next to better sustain heart failure patients’ lives.

Abbott officials on the panel include Chris Cotter, principal R&D engineer, Chad Dague, staff systems engi…

Where are LVADs headed in the future?

The HeartMate 3 LVAD. [Image courtesy of LVAD]Abbott (NYSE:ABT) became the dominant provider of left ventricular assist devices (LVADs) after Medtronic’s decision last year to leave the market.

The Abbott HeartMate 3‘s advantages include its Full MagLev flow technology — which involves a free-floating magnetically levitated rotor that prevents surface-to-surface contact that could cause blood trauma. In addition, system batteries provide up to 17 hours of uninterrupted power, and the LVAD’s creators designed the system’s HeartMate Touch communications system to be intuitive and user-friendly.

Join us at DeviceTalks Boston on May 10-11, 2022, and find out where top Abbott officials would like to take LVADs next to better sustain heart failure patients’ lives.

Abbott officials on the panel include Chris Cotter, principal R&D engineer, Chad Dague, staff systems engineer, and Kevin Bourque, VP of R&D.

(Go to DeviceTa…

How medtech is tackling supply chain challenges

A host of medical device companies with manufacturing in Puerto Rico found their supply chains impacted by Hurricane Maria in 2017. It was a harbinger of what was to come. [Image is public domain]Join us at DeviceTalks Boston on May 10-11 to hear how medical device companies are propping open supply lines and ensuring a steady flow of products to customers in a constantly changing world.

Sharing best practices is more important than ever because supply chain challenges aren’t expected to diminish post-pandemic. That’s because superstorms, fires, droughts and other extreme events driven by climate change are already straining the industry’s supply chain — and it could get a lot worse.

(Go to DeviceTalks Boston’s site to register!)

Over the two-day meeting we’ll hear how companies large and small are adapting to new demands, including:

How Viant and Vapotherm combined forces to meet unforeseen demands brought on by the COVID-19 pandemi…

How medtech is tackling supply chain challenges

A host of medical device companies with manufacturing in Puerto Rico found their supply chains impacted by Hurricane Maria in 2017. It was a harbinger of what was to come. [Image is public domain]

Join us at DeviceTalks Boston on May 10-11 to hear how medical device companies are propping open supply lines and ensuring a steady flow of products to customers in a constantly changing world.

Sharing best practices is more important than ever because supply chain challenges aren’t expected to diminish post-pandemic. That’s because superstorms, fires, droughts and other extreme events driven by climate change are already straining the industry’s supply chain — and it could get a lot worse.

(Go to DeviceTalks Boston’s site to register!)

Over the two-day meeting we’ll hear how companies large and small are adapting to new demands, including:

How Viant and Vapotherm combined forces to meet unforesee…

What is the future of cardiac ablation?

Boston Scientific in July 2021 exercised its option to acquire the remaining shares of PFA tech developer Farapulse. [Image courtesy of Boston Scientific]Pulsed-field ablation (PFA) — a non-thermal method for cardiac ablation — has the potential to positively disrupt the atrial fibrillation market.

Amid the excitement around the technology, Medtronic announced in January that it would acquire cardiac mapping and ablation technology developer Affera for nearly $1 billion. Meanwhile, Boston Scientific in February closed its $1.75 billion acquisition of Baylis Medical — the creator of advanced transseptal puncture platforms to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart. Months before, Boston Scientific exercised its option to acquire the remaining shares of PFA tech developer Farapulse.

Come to DeviceTalks Boston — May 10-11, 2022 — and hear from leaders at Boston Scientific, Medtronic an…

What is the future of cardiac ablation?

Boston Scientific in July 2021 exercised its option to acquire the remaining shares of PFA tech developer Farapulse. [Image courtesy of Boston Scientific]

Pulsed-field ablation (PFA) — a non-thermal method for cardiac ablation — has the potential to positively disrupt the atrial fibrillation market.

Amid the excitement around the technology, Medtronic announced in January that it would acquire cardiac mapping and ablation technology developer Affera for nearly $1 billion. Meanwhile, Boston Scientific in February closed its $1.75 billion acquisition of Baylis Medical — the creator of advanced transseptal puncture platforms to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart. Months before, Boston Scientific exercised its option to acquire the remaining shares of PFA tech developer Farapulse.

Come to DeviceTalks Boston — May 10-11, 2…

Discover where this artificial pancreas pioneer sees medtech development going

Frank Doyle — a prolific medical device inventor and Harvard engineering school leader — will discuss the future of medtech development during DeviceTalks Boston, May 10–11, 2022.

A pioneer in developing artificial pancreas technology to treat diabetes, Doyle will share his insights on the future of medical device development, including the expanding role of robotics and artificial intelligence.

(Register today!)

Doyle is the Dean of the Harvard John A. Paulson School of Engineering and Applied Sciences. His success earned him election into the National Academy of Engineering last year (and National Academies of Medicine and Inventors before that).

Doyle will hit upon several critical areas during his keynote presentation at DeviceTalks Boston including:

What lessons he learned from the many years spent developing the complicated systems and algorithms of an artificial pancreas and providing the support necessary to bring it to market. How, i…

Discover where this artificial pancreas pioneer sees medtech development going

Frank Doyle — a prolific medical device inventor and Harvard engineering school leader — will discuss the future of medtech development during DeviceTalks Boston, May 10–11, 2022.

A pioneer in developing artificial pancreas technology to treat diabetes, Doyle will share his insights on the future of medical device development, including the expanding role of robotics and artificial intelligence.

(Register today!)

Doyle is the Dean of the Harvard John A. Paulson School of Engineering and Applied Sciences. His success earned him election into the National Academy of Engineering last year (and National Academies of Medicine and Inventors before that).

Doyle will hit upon several critical areas during his keynote presentation at DeviceTalks Boston including:

What lessons he learned from the many years spent developing the complicated systems and algorithms of an artificial pancreas and providing the support necessary to bring it to market. How, i…

DeviceTalks Boston returns with a unique approach for medtech connections and development

DeviceTalks Boston speakers include Meghan Scanlon, senior vice president at Boston Scientific and president of its urology and pelvic health business. [Photo courtesy of Boston Scientific]A few months back, I wrote what was best described by a colleague as a “salty” Medical Design & Outsourcing column in which I demanded conference organizers like myself step up our game if we expect to bring back attendees.

“For too long, conference organizers have relied upon a potent cocktail of FOMO and habit,” I wrote in one particularly briny portion. “Sure, organizers try to amp up content, introduce cool partnering apps and a few gimmicks. (One recent healthcare meeting had puppies, actual puppies … gimmicky, but intriguing.)”

Here I am, four months later, and I still agree with me!

We’ve been working harder — and smarter — to assemble the agenda of DeviceTalks Boston, coming up May 10–11 at the Boston Convention and Exhibition Center. And while I can’t deliver…